To the Editor Dr Nicholls and colleagues found that adding evolocumab vs placebo to statin treatment among patients with coronary disease resulted in a 1% greater decrease in percent atheroma volume (PAV), measured by serial intravascular ultrasonography (IVUS) imaging, after 76 weeks.1 Unfortunately, IVUS examinations have inherent variability.2 Even in the best of laboratories, there are always measurement reproducibility errors but also intraoperator and interoperator variability in the actual plaque measurements.2
Murray SW. Evolocumab Added to Statins to Reduce Progression of Coronary Atherosclerosis. JAMA. 2017;317(16):1690. doi:10.1001/jama.2017.3440
Customize your JAMA Network experience by selecting one or more topics from the list below.